Showing 1 - 7 results of 7 for search 'Anna L. Godfrey', query time: 0.04s Refine Results
  1. 1
    Clonal Architecture in Myeloproliferative Neoplasms: Old Dog, New Tricks?

    Clonal Architecture in Myeloproliferative Neoplasms: Old Dog, New Tricks? by Anna L. Godfrey

    Published 2023-06-01
    Get full text
    Article
  2. 2
    Low-Risk Essential Thrombocythemia: A Comprehensive Review

    Low-Risk Essential Thrombocythemia: A Comprehensive Review by Andrew J. Robinson, Anna L. Godfrey

    Published 2021-02-01
    Get full text
    Article
  3. 3
    Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia

    Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia by Anna L. Godfrey, Edwin Chen, Francesca Pagano, Yvonne Silber, Peter J. Campbell, Anthony R. Green

    Published 2013-05-01
    Get full text
    Article
  4. 4
    RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability

    RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability by Edwin Chen, Jong Sook Ahn, David B. Sykes, Lawrence J. Breyfogle, Anna L. Godfrey, Jyoti Nangalia, Amy Ko, Daniel J. DeAngelo, Anthony R. Green, Ann Mullally

    Published 2015-12-01
    Get full text
    Article
  5. 5
    DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype

    DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype by Jyoti Nangalia, Francesca L. Nice, David C. Wedge, Anna L Godfrey, Jacob Grinfeld, Clare Thakker, Charlie E. Massie, Joanna Baxter, David Sewell, Yvonne Silber, Peter J. Campbell, Anthony R. Green

    Published 2015-11-01
    Get full text
    Article
  6. 6
    STAT1 activation in association with JAK2 exon 12 mutations

    STAT1 activation in association with JAK2 exon 12 mutations by Anna L. Godfrey, Edwin Chen, Charles E. Massie, Yvonne Silber, Francesca Pagano, Beatriz Bellosillo, Paola Guglielmelli, Claire N. Harrison, John T. Reilly, Frank Stegelmann, Fontanet Bijou, Eric Lippert, Jean-Michel Boiron, Konstanze Döhner, Alessandro M. Vannucchi, Carlos Besses, Anthony R. Green

    Published 2016-01-01
    Get full text
    Article
  7. 7
    Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis

    Tamoxifen for the treatment of myeloproliferative neoplasms: A Phase II clinical trial and exploratory analysis by Zijian Fang, Giuditta Corbizi Fattori, Thomas McKerrell, Rebecca H. Boucher, Aimee Jackson, Rachel S. Fletcher, Dorian Forte, Jose-Ezequiel Martin, Sonia Fox, James Roberts, Rachel Glover, Erica Harris, Hannah R. Bridges, Luigi Grassi, Alba Rodriguez-Meira, Adam J. Mead, Steven Knapper, Joanne Ewing, Nauman M. Butt, Manish Jain, Sebastian Francis, Fiona J. Clark, Jason Coppell, Mary F. McMullin, Frances Wadelin, Srinivasan Narayanan, Dragana Milojkovic, Mark W. Drummond, Mallika Sekhar, Hesham ElDaly, Judy Hirst, Maike Paramor, E. Joanna Baxter, Anna L. Godfrey, Claire N. Harrison, Simón Méndez-Ferrer

    Published 2023-11-01
    Get full text
    Article

Search Tools: